Cite
HARVARD Citation
Larkin, J. et al. (n.d.). 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067). European journal of cancer. pp. S664-S665. [Online].